Proactively manage your pharmacy inventory
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
Manage your formulary budget
Drug patents …
… from Kazakhstan to Kalamazoo
Anticipate generic drug launch
Find generic entry opportunities
|Title:||Abuse-resistant amphetamine prodrugs|
|Abstract:||The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.|
|Inventor(s):||Mickle; Travis (Coralville, IA), Krishnan; Suma (Belvedere, CA), Bishop; Barney (Annandale, VA), Lauderback; Christopher (Blacksburg, VA), Moncrief; James Scott (Christiansburg, VA), Oberlender; Robert (Blacksburg, VA), Piccariello; Thomas (Blacksburg, VA), Paul; Bernhard J. (Lexington, MA), Verbicky; Christopher A. (Broadalbin, NY)|
|Assignee:||Shire LLC (Florence, KY)|
1. The compound, L-lysine-d-amphetamine dimesylate.
2. A compound as defined in claim 1, having a water content of about 0% to about 5% by Karl Fischer analysis.
3. A compound as defined in claim 1, having a water content of about 0.1% to about 3% by Karl Fischer analysis.
4. A compound as defined in claim 1, having a water content of about 0.25% to about 2% by Karl Fischer analysis.